Table 5. Effect of home zinc on rate of sick visits to Lwak clinic, hospitalization, and mortality, western Kenya, from February 2008–March 2009, controlling for baseline rates of morbidity in home zinc and comparison villages.

	Pre-intervention*		Intervention period†		Adjusted RR‡ (CI 95%)
	Home zinc	Comparison	Home zinc	Comparison
Person-years observed	2001	2245	598	625
Diarrhea	0.098	0.118	0.22	0.31	0.99 [0.73–1.33]
Diarrhea plus reported fever	0.089	0.102	0.21	0.27	1.02 [0.76–1.39]
Diarrhea and malaria	0.025	0.023	0.10	0.14	0.87 [0.57–1.34]
Severe diarrhea	0.040	0.046	0.10	0.11	1.14 [0.72–1.79]
Diarrhea hospitalization	0.027	0.034	0.06	0.09	0.82 [0.49–1.36)
Acute Respiratory Illness	0.406	0.464	0.86	1.18	0.93 [0.76–1.13]
ALRI	0.053	0.065	0.11	0.15	0.95 [0.65–1.40]
ALRI hospitalization	0.035	0.049	0.06	0.09	0.93 [0.56–1.53]
Acute febrile illness	0.030	0.049	0.16	0.22	1.20 [0.84–1.71]
Malaria (Blood smear+)	0.033	0.040	0.49	0.77	0.89 [0.70–1.12]
All-cause hospitalization	0.093	0.126	0.17	0.29	0.79 [0.57–1.09]
Mortality	0.023	0.029	0.02	0.04	0.69 [0.34–1.41]

Per-treatment analysis includes only children who received at least one course of zinc in home zinc villages and one course of ORS in comparison villages. Rates are given as episodes per person-year.

*Pre-intervention period was October 2006 to November 2007.

^†While pre-intervention includes all children in the village of appropriate age, the intervention period only includes those enrolled in the home zinc study who took one course of recommended treatment for diarrhea.

^‡Rate ratio is comparing rates between home zinc and comparison groups during the intervention period, adjusted for pre-intervention rates of same syndrome in the child’s village, distance of child’s compound to Lwak Hospital and child’s age.